Volume 16, Number 9—September 2010
Dispatch
KI and WU Polyomaviruses and CD4+ Cell Counts in HIV-1–infected Patients, Italy
Muhammed Babakir-Mina, Massimo Ciccozzi, Francesca Farchi, Massimiliano Bergallo, Rossana Cavallo, Gaspare Adorno, Carlo Federico Perno, and Marco Ciotti
Table 2
Treatment regimens for 11 HIV-1–positive patients co-infected with KI or WU polyomavirus, Italy, 2004–2009*
| Patient no. | KIPyV | WUPyV | HAART |
|---|---|---|---|
| 1 | + | – | None |
| 2 | + | – | None |
| 3 | + | – | None |
| 4 | + | – | NRTI: FTC, TDF; PI: ATV, RTV |
| 5 | – | + | NNRTI: EFV; NRTI: 3TC, TDF |
| 6 | – | + | NNRTI: NVP; NRTI: 3TC, AZT |
| 7 | – | + | NRTI: 3TC, AZT; PI: ATV, RTV |
| 8 | – | + | NNRTI: NVP; NRTI: ABC, TDF |
| 9 | – | + | None |
| 10 | – | + | NNRTI: EFV; NRTI: 3TC, D4T |
| 11 | – | + | None |
*KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; TDF, tenofovir; PI, protease inhibitor; ATV, atazanavir; RTV, ritonavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; EFV, Efavirenz; 3TC, lamivudine; NVP, nevirapine; AZT, azidothymidine; ABC, D4T, stavudine.
Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.